1. <th id="ya0vw"><sup id="ya0vw"></sup></th>
      <pre id="ya0vw"><small id="ya0vw"><input id="ya0vw"></input></small></pre>
    2. <pre id="ya0vw"><small id="ya0vw"><p id="ya0vw"></p></small></pre>
      <strike id="ya0vw"></strike>
    3. <code id="ya0vw"></code>

      www.247cinema.cn 提示:

      本信息僅供醫學專業人士參考,如果您是醫學專業人士,請點擊確定后進入。 如果不是,請點擊取消。

      取消 確定

      Products and services

      In 3SBio, meeting the needs of patients is the core of all actions.

      Our global list of drug combinations

      The following is a list of products listed by our company, which is only for medical professionals to refer to.

      TPIAO (Recombinant human thrombopoietin (rhTPO))

      In 2005, TPIAO was listed and has been approved by the NMPA for two indications that are the treatment of chemotherapy-induced thrombopenia (approved in 2005) and immune thrombocytopenia (ITP) (approved in 2010), which is included in the National Medical Insurance Catalogue as a Category B drug of western medicine.

      Indication Manufacturing base Dosage form & Dosage

      Treatment for chemotherapy-induced thrombocytopenia (CIT);
      Treatment for immune thrombocytopenia (ITP).

      Shenyang manufacturing base

      7500 U/1 ml; 15000 U/1 ml

      Cipterbin (Inetetamab for?Injection)

      Cipterbin was formally approved in June 2020 as the first innovative anti-HER2 monoclonal antibody in China with the engineered Fc region, optimized production process and a stronger ADCC effect. Research showed that in combination with chemotherapy drugs, it can significantly reduce the risk of disease progression in patients with HER2-positive metastatic breast cancer, improve the objective response rate, and prolong the progression-free survival of the patients.

      Indication Manufacturing base Dosage form & Dosage
      This product is indicated, in combination with vinorelbine, for the treatment of patients with HER2-positive metastatic breast cancer, who have received one or more chemotherapy regimens. Shanghai manufacturing base 50mg/bottle

      Intefen (Human Interferon α2a for Injection)

      In April 1995, Intefen was approved to be manufactured by NMPA.In December 1995, Intefen was launched and is included in the National Medical Insurance Catalogue as a Category B drug.

      Indication Manufacturing base Dosage form & Dosage
      Treatment of lymphatic or hematopoietic malignancies and viral infections: adult chronic hepatitis B, acute and chronic hepatitis C and condyloma acuminata. Shenyang manufacturing base Injection - 1,000,000 IU/ml, 3,000,000 IU/ml, 5,000,000 IU/ml;
      Freeze-dried powder - 1,000,000 IU/ml, 3,000,000 IU/ml, 5,000,000 IU/ml.

      Inleusin (Human Interleukin-2 for Injection)

      In June 1995, NMPA production approval documents were obtained for Inleusin. This product was launched in March 1996 and is included in the National Medical Insurance Catalogue as a Category B drug.

      Indication Manufacturing base Dosage form & Dosage
      Treatment of renal cell carcinoma, melanoma, thoracic fluid build-up caused by cancer, and tuberculosis. Shenyang manufacturing base 100,000 IU/bottle; 200,000 IU/bottle; 500,000 IU/bottle; 1,000,000 IU/bottle
      91精品国产综合久久,亚洲国产综合91精品,久久久久亚洲AV无码专区首页